GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

HROW · Jun 30, 2026

HARROW, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001628280-26-055271General Corporate
Capex intensity50thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.69% · OPTIONAL · VALID

Operating cash generation8thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-13.81% · OPTIONAL · VALID

Revenue growth13thOwn-history percentile · N=8
Evidence method

Yoy · gp.fundamentals.revenue

10.85% · CORE · VALID

Inventory pressure67thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

23.93% · OPTIONAL · VALID

Gross margin50thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.gross_margin

71.27% · CORE · VALID

Operating margin25thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.operating_margin

-15.58% · CORE · VALID

R&D intensity92thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

11.42% · OPTIONAL · VALID

SBC intensity25thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

5.36% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesHistory building
Jun 30, 20230/8 normalizedLevel 3Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/9 normalizedLevel 3Sep 30, 20240/9 normalizedLevel 3Dec 31, 20240/9 normalizedLevel 3Mar 31, 20250/9 normalizedLevel 3Jun 30, 20258/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Increased
Previous
0.44%
Current
0.69%
Delta
0.26%
Cash Generation Increased
Previous
-20.34%
Current
-13.81%
Delta
6.54%
Growth Increased
Previous
-7.58%
Current
10.85%
Delta
18.44%
Inventory Pressure Decreased
Previous
37.32%
Current
23.93%
Delta
-13.39%
Margin Increased
Previous
61.18%
Current
71.27%
Delta
10.09%
Profitability Increased
Previous
-49.95%
Current
-15.58%
Delta
34.37%
R And D Intensity Decreased
Previous
13.34%
Current
11.42%
Delta
-1.91%
Sbc Intensity Decreased
Previous
8.68%
Current
5.36%
Delta
-3.32%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Compared To · Pharmaceutical Preparations peers →Has State · HARROW, INC. →Transitioned To · HROW Fundamental State →Transitioned To · HROW CAPEX_INTENSITY_INCREASED →Transitioned To · HROW CASH_GENERATION_INCREASED →Transitioned To · HROW GROWTH_INCREASED →Transitioned To · HROW INVENTORY_PRESSURE_DECREASED →Transitioned To · HROW MARGIN_INCREASED →Transitioned To · HROW PROFITABILITY_INCREASED →Transitioned To · HROW R_AND_D_INTENSITY_DECREASED →Transitioned To · HROW SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.